Cargando…

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring

INTRODUCTION: Progastrin-releasing peptide (proGRP), a precursor of GRP, has been recently reported as a putative circulating biomarker for differential diagnosis between non–small cell lung cancer (NSCLC) and SCLC. We evaluated the diagnostic effectiveness of proGRP to differentiate patients with N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barchiesi, Vittoria, Simeon, Vittorio, Sandomenico, Claudia, Cantile, Monica, Cerasuolo, Dionigio, Chiodini, Paolo, Morabito, Alessandro, Cavalcanti, Ernesta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267854/ https://www.ncbi.nlm.nih.gov/pubmed/34252174 http://dx.doi.org/10.33393/jcb.2021.2212

Ejemplares similares

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy
por: Cavalcanti, Ernesta, et al.
Publicado: (2016)

Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases
por: Sabatino, Rocco, et al.
Publicado: (2017)

Instability of Plasma and Serum Progastrin-Releasing Peptide During Repeated Freezing and Thawing
por: Lee, Jae-Eun, et al.
Publicado: (2016)

Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients
por: Li, Li, et al.
Publicado: (2020)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy
por: Li, Ming, et al.
Publicado: (2020)

Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China
por: Wu, Xiao‐Yuan, et al.
Publicado: (2018)

Aptamer based surface plasma resonance assay for direct detection of neuron specific enolase and progastrin-releasing peptide (31-98)
por: Sun, Linlin, et al.
Publicado: (2021)

Prognostic Value of Plasma hPG(80) (Circulating Progastrin) in Metastatic Renal Cell Carcinoma
por: Kohli, Manish, et al.
Publicado: (2021)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
por: Dupuy, Marie, et al.
Publicado: (2022)

Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors
por: TUTAR, Nuri, et al.
Publicado: (2019)

Targeting progastrin enhances radiosensitization of colorectal cancer cells
por: Kowalski-Chauvel, Aline, et al.
Publicado: (2017)

Association between Serum Progastrin Biomarker Level and Gastric Cancer
por: Amjadi, Omolbanin, et al.
Publicado: (2022)

Association between post-operative hPG(80) (circulating progastrin) detectable level and worse prognosis in glioblastoma
por: Doucet, L., et al.
Publicado: (2023)

hPG(80) (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study
por: Casile, Melanie, et al.
Publicado: (2023)

Acute effects of N‐terminal progastrin fragments on gastric acid secretion in man
por: Goetze, Jens P., et al.
Publicado: (2017)

Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer
por: Yashi, Masahiro, et al.
Publicado: (2022)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
por: Prieur, Alexandre, et al.
Publicado: (2023)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Comparison of seven serum assays on four automatic analysers
por: Sacchetti, Lucia, et al.
Publicado: (1989)

Progastrin Represses the Alternative Activation of Human Macrophages and Modulates Their Influence on Colon Cancer Epithelial Cells
por: Hernández, Carlos, et al.
Publicado: (2014)

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients
por: You, Benoit, et al.
Publicado: (2019)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC
por: Mohan, Sumitra, et al.
Publicado: (2020)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

The G-protein coupled receptor 56, expressed in colonic stem and cancer cells, binds progastrin to promote proliferation and carcinogenesis
por: Jin, Guangchun, et al.
Publicado: (2017)

Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease
por: Iams, Wade T., et al.
Publicado: (2020)

Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
por: Dong, Juanjuan, et al.
Publicado: (2021)

Progastrin production transitions from Bmi1(+)/Prox1(+) to Lgr5(high) cells during early intestinal tumorigenesis
por: Giraud, J., et al.
Publicado: (2020)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC)
por: Messaritakis, Ippokratis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tns3emqmd1cbig3i3tu6l7erpm